루트K

195990KOSDAQ

51.5 / 100

Reference Date: 2026-09-08

Financial Score22.0 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 1.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

AB ProBio operates three core business segments: a machine tool division specializing in small machining centers (UT and MAX series), a biopharmaceutical development division that acquired rights to develop dual-antibody drugs targeting HER2 and VEGF from Abpro Corporation, and a semiconductor equipment division expanded through the acquisition of ANAH in 2023. The company produces high-performance machining centers tailored for IT and electronics manufacturing, while advancing biopharmaceutical R&D in Asia, CIS countries, and the Middle East.

Number of Employees

43people

Average Salary

0.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.39Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-60.38Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

22.87Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲12.8% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼3.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -31.2% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (24%)

Current 1,299Won52-week high 3,38252-week low 630

1-month return3.0Point

1m 1.09% (flat)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral주요사항보고서(자기전환사채만기전취득결정)2026-08-28
Neutral반기보고서 (2026.06)2026-08-14